Study #2022-0888
A phase 1/2 open-label multicenter trial to characterize the safety, tolerability, and preliminary efficacy of CFT1946 as monotherapy and combination Therapy in subjects with BRAF-V600 mutant solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
CFT1946, Trametinib, Cetuximab
Description
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors, Melanoma, NSCLC, CRC, ATC
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-798-1207
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.